Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-CSF for Oral Mucositis in Nasopharyngeal Carcinoma
NCT06472739Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2023
- Primary completion
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sargramostim in oral mucositis (OM) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Incidence of severe oral mucositis (grade 3+) up to 1.5 months. Started Sep 2023; status: recruiting.
02
Drugs
sargramostim
03
Conditions
oral mucositis (OM)
Beyond the preview
Go deeper on NCT06472739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06472739.